DK2009025T3 - Fremgangsmåde til hæmning af osteoklast-aktivitet - Google Patents

Fremgangsmåde til hæmning af osteoklast-aktivitet

Info

Publication number
DK2009025T3
DK2009025T3 DK08015570.8T DK08015570T DK2009025T3 DK 2009025 T3 DK2009025 T3 DK 2009025T3 DK 08015570 T DK08015570 T DK 08015570T DK 2009025 T3 DK2009025 T3 DK 2009025T3
Authority
DK
Denmark
Prior art keywords
receptors
osteoclast activity
inhibiting osteoclast
isolated
disclosed
Prior art date
Application number
DK08015570.8T
Other languages
Danish (da)
English (en)
Inventor
Dirk M Anderson
Laurent J Galibert
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK2009025T3 publication Critical patent/DK2009025T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08015570.8T 1998-05-14 1999-05-13 Fremgangsmåde til hæmning af osteoklast-aktivitet DK2009025T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8548798P 1998-05-14 1998-05-14
US11083698P 1998-12-03 1998-12-03
EP99923021A EP1076699B1 (en) 1998-05-14 1999-05-13 Method of inhibiting osteoclast activity

Publications (1)

Publication Number Publication Date
DK2009025T3 true DK2009025T3 (da) 2011-11-14

Family

ID=26772773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08015570.8T DK2009025T3 (da) 1998-05-14 1999-05-13 Fremgangsmåde til hæmning af osteoklast-aktivitet

Country Status (12)

Country Link
US (2) US20050089522A1 (https=)
EP (2) EP1076699B1 (https=)
JP (1) JP2002514418A (https=)
AT (2) ATE412746T1 (https=)
AU (1) AU762574B2 (https=)
CA (1) CA2328140C (https=)
CY (1) CY1111912T1 (https=)
DE (1) DE69939822D1 (https=)
DK (1) DK2009025T3 (https=)
ES (1) ES2317694T3 (https=)
PT (1) PT2009025E (https=)
WO (1) WO1999058674A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP1803816A3 (en) * 1996-12-13 2007-09-26 Schering Corporation Mammalian cell surface antigens; related reagents
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
KR100496063B1 (ko) 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
US20030017151A1 (en) * 2001-05-17 2003-01-23 Dougall William C. Therapeutic use of rank antagonists
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2463478A1 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
JP5191487B2 (ja) * 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ATE240394T1 (de) * 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
MX9709447A (es) * 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP1803816A3 (en) 1996-12-13 2007-09-26 Schering Corporation Mammalian cell surface antigens; related reagents
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
KR100496063B1 (ko) * 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
DE60034871T2 (de) 1999-09-03 2008-01-17 Amgen Inc., Thousand Oaks Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2105449T3 (da) 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Also Published As

Publication number Publication date
CY1111912T1 (el) 2015-11-04
WO1999058674A3 (en) 2000-02-10
DE69939822D1 (de) 2008-12-11
JP2002514418A (ja) 2002-05-21
US20050089522A1 (en) 2005-04-28
CA2328140C (en) 2012-03-13
ES2317694T3 (es) 2009-04-16
EP2009025A1 (en) 2008-12-31
ATE412746T1 (de) 2008-11-15
WO1999058674A2 (en) 1999-11-18
ATE517916T1 (de) 2011-08-15
EP2009025B1 (en) 2011-07-27
EP1076699A2 (en) 2001-02-21
AU3988899A (en) 1999-11-29
US20090004196A1 (en) 2009-01-01
EP1076699B1 (en) 2008-10-29
CA2328140A1 (en) 1999-11-18
US7790684B2 (en) 2010-09-07
PT2009025E (pt) 2011-09-19
AU762574B2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
DK2009025T3 (da) Fremgangsmåde til hæmning af osteoklast-aktivitet
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DE69819786D1 (de) Biozidzusammensetzungen zur behandlung vom wasser
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9811099A (pt) Inibidores de urocinase
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
DK1129093T3 (da) Pyrazolopyrimidinonderivater til behandling af impotens
DK1173059T3 (da) Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
BRPI0414215A (pt) tienopirazóis
DK0965631T3 (da) Højstabile planteolier
EP1131332A4 (en) ANTISENSE MODULATION OF THE INHIBITOR KAPPA B KINASE-BETA EXPRESSION
EP1131107A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INHIBITOR-KAPPA-B-KINASE-ALPHA
EP1218398A4 (en) ANTISENSE MODULATION OF P13 KINASE P110 BETA EXPRESSION
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
TR200200278T2 (tr) Kalsilitik bileşimler
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
BR9704565B1 (pt) composições herbicidas sinérgicas para o cultivo de cana-de-açúcar, e método para o controle de plantas indesejadas.
CL2004001461A1 (es) Compuestos derivados de 1,2,3,4-tetrahidropirimidina, composicion farmaceutica y su procedimiento de preparacion, procedimiento de preparacion, utiles para tratar o prevenir la hepatitis c.
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen